Sglt-2 insulin Matthews D, Fulcher G, Perkovic V, et al. Ef  cacy and safety of canagliflozin,an inhibitor of sodium glucose co-transporter 2, added on to insulin therapy with or without oral agents in type 2 diabetes. Poster presented at: The 48 th Annual Meeting of the European Association for the Study of Diabetes (EASD),October 1-5, 2012, Berlin, Germany. Janssen Research & Development, LLC. (Posted 2009). CANVAS- CANagli  ozin cardioVascular Assessment Study (NCT ). (Accessed 15 Jan 2013). Rosenstock J, Davies M, Dumas R, et al. Effects of canagli  ozin added onto basal insulin with or without other antihyperglycemic agents in type 2 diabetes. Poster presented at: The 73rd Scienti  c Sessions of the American Diabetes Association (ADA), June 21-25, 2013, Chicago, IL.

Canvas SGLT-2 + Basal /bolus +/- other agents Mathews

Dapa insulin- insulin sparing Placebo-Controlled Trial of Insulin-Sparing Effect In patients with type 2 diabetes who had inadequate glycaemic control despite high-dose insulin plus oral antidiabetic drugs that act via insulin-dependent mechanisms (metformin, pioglitazone or rosiglitazone), the addition of dapagliflozin 10 or 20 mg/ day, after halving the insulin dosage at baseline, was associated with more favourable effects on HbA1c, FPG, PPG and body weight than placebo in a 12-week, randomized, double-blind trial.[43] A total of 71 patients were randomized in a 1 : 1 : 1 ratio to the three treatment groups, and statistical analyses were not reported. For the primary endpoint of mean change from baseline in HbA1c at week 12, results for dapagliflozin 10 mg/ day, 20 mg/ day and placebo were %, % and %, respectively. Wilding JPH, Norwood P, T’Joen C, et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009 Sep; 32 (9):